Modern methods for desensitization protocol rely heavily on combined apheresis therapy and Rituximab, a chimeric (murine and human) anti-CD20 antibody used in AB0 incompatible kidney transplants. Severe infusion related reactions due to the administration of Rituximab are reported in 10% of patients. These adverse reactions may hinder the completion of the desensitization protocol. Therefore, it's useful to test alternative B cell depleting therapies. Our clinical case focuses on a 41-year-old male who developed an adverse infusion reaction following the administration of Rituximab and was given Ofatumumab as an alternative treatment. Ofatumumab is a fully humanized monoclonal anti-CD20 antibody. As a fully humanized antibody, Ofatumumab may avoid immunogenic reactions. The patient tolerated the administration of the drug showing no signs of adverse side effects and with good clinical efficacy. Our case report suggest that Ofatumumab is a valid alternative B cell depleting agent.

Mancianti, N., Monaci, G., Rollo, F., Buracchi, P., Guarnieri, A., Di Luca, M., et al. (2017). Primo Case Report di utilizzo dell’Ofatumumab nel trapianto renale AB0 incompatibile [First case report of using Ofatumumab in kidney transplantation AB0 incompatible]. GIORNALE ITALIANO DI NEFROLOGIA, 34(6), 1-5.

Primo Case Report di utilizzo dell’Ofatumumab nel trapianto renale AB0 incompatibile [First case report of using Ofatumumab in kidney transplantation AB0 incompatible]

Guarnieri A;Garosi G
2017-01-01

Abstract

Modern methods for desensitization protocol rely heavily on combined apheresis therapy and Rituximab, a chimeric (murine and human) anti-CD20 antibody used in AB0 incompatible kidney transplants. Severe infusion related reactions due to the administration of Rituximab are reported in 10% of patients. These adverse reactions may hinder the completion of the desensitization protocol. Therefore, it's useful to test alternative B cell depleting therapies. Our clinical case focuses on a 41-year-old male who developed an adverse infusion reaction following the administration of Rituximab and was given Ofatumumab as an alternative treatment. Ofatumumab is a fully humanized monoclonal anti-CD20 antibody. As a fully humanized antibody, Ofatumumab may avoid immunogenic reactions. The patient tolerated the administration of the drug showing no signs of adverse side effects and with good clinical efficacy. Our case report suggest that Ofatumumab is a valid alternative B cell depleting agent.
Mancianti, N., Monaci, G., Rollo, F., Buracchi, P., Guarnieri, A., Di Luca, M., et al. (2017). Primo Case Report di utilizzo dell’Ofatumumab nel trapianto renale AB0 incompatibile [First case report of using Ofatumumab in kidney transplantation AB0 incompatible]. GIORNALE ITALIANO DI NEFROLOGIA, 34(6), 1-5.
File in questo prodotto:
File Dimensione Formato  
GItalNefrol2017.pdf

non disponibili

Descrizione: Free full-text sul sito dell'editore
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 914.37 kB
Formato Adobe PDF
914.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1215915